Result of AGM 2019

RNS Number : 4314Q
Dechra Pharmaceuticals PLC
18 October 2019
 

 

 

Date: 18 October 2019

 

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

 

 

AGM Meeting Date: 1.00 pm on 18 October 2019

 

Issued Share Capital at meeting date: 102,810,767

 

Number of shareholders in attendance: 9

 

All resolutions were passed on a show of hands.

 

Details of the proxy voting instructions lodged prior to the AGM are set out below:

 

Resolution (No. as noted on proxy form)

 

Total For (1)

Total Against

Withheld (2)


No. of votes

% of vote

No. of votes

% of vote

No. of votes

Resolution 1:

To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report

 

73,600,333

100

1,169

0.00

124,694

Resolution 2:

To approve the Directors' Remuneration Report

 

72,519,866

99.27

533,633

0.73

672,695

Resolution 3:

To declare a final dividend

 

73,723,024

100

3,172

0.00

0

Resolution 4:

To elect Lisa Bright

 

71,027,627

96.34

2,697,283

3.66

1,286

Resolution 5:

To re-elect William Anthony Rice

 

64,700,457

88.18

8,674,437

11.82

351,301

Resolution 6:

To re-elect Ian Page

 

72,894,442

98.87

830,875

1.13

879

Resolution 7:

To re-elect Anthony Griffin

 

72,692,473

98.87

829,706

1.13

204,017

Resolution 8:

To re-elect Julian Heslop

 

72,655,439

98.55

1,069,878

1.45

879

Resolution 9:

To re-elect Ishbel Macpherson

 

72,432,244

98.32

1,238,292

1.68

55,660

Resolution 10:

To re-elect Lawson Macartney

 

72,658,987

98.55

1,066,330

1.45

879

Resolution 11:

To re-appoint PricewaterhouseCoopers as external auditor of the Company

 

73,101,156

99.98

11,756

0.02

613,283

Resolution 12:

To authorise the Audit Committee to determine the remuneration of the external auditor

 

73,723,991

100

2,205

0.00

0

Resolution 13:

To authorise the Directors to allot shares to specific limits

 

69,401,484

94.13

4,324,496

5.87

216

Resolution 14:

To disapply the pre-emption rights

 

73,525,799

99.73

199,168

0.27

1,229

Resolution 15:

To disapply additional
pre-emption rights

 

71,956,054

97.60

1,768,826

2.40

1,315

Resolution 16:

To authorise the Company to purchase its own shares

 

72,768,511

99.00

734,677

1.00

223,007

Resolution 17:

To call general meetings (other than an AGM) on not less than 14 clear days' notice

 

72,473,824

98.30

1,252,372

1.70

0

Resolution 18:

To adopt New Articles of Association

 

73,625,816

99.87

99,231

0.13

1,149

 

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 13 were ordinary resolutions, requiring more than 50% of shareholder votes to be "For" the resolutions.

4.   Resolutions 14 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "For" the resolutions.

5.   Votes tendered in respect of 73,726,196 shares representing 71.71% of the issued share capital.

 

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 

For further information, please contact:

 

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

 

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGLLFSVIVLTLIA
UK 100

Latest directors dealings